Genetic Analyzer Systems Sales banking on Increased Government Funding

Unwavering R&D initiatives is compelling government entities to sanction research projects incorporating advanced genetic analyzer systems

Fact.MR, Rockville MD: The ongoing study on genetic analyzer systems market being conducted by Fact.MR forecasts an optimistic outlook through 2021 and beyond. The novel coronavirus pandemic provided additional tailwinds through FY 2020-21, as healthcare experts were extensively engaged in discovering key breakthroughs to combat the deadly virus.

Prior to the pandemic’s onset, the market was already posting impressive gains, majorly underpinned by unceasing research initiatives by multiple entities. For instance, the Department of Biotechnology (DBT) in India initiated the Genome India Project (GIP) on 3rd January 2020. Modeled on the lines of the Human Genome Project, this initiative aims to collect 10,000 genetic samples from citizens across India, to build a reference genome. This would aid in understanding of the nature of diseases affecting the Indian population.

Similarly, in the US, aggregate spending on genomics research from 34 funding sources averaged around US$ 2.9 billion between 2003 and 2006. Recently, in August 2019, the National Institutes of Health led project titled All of Us, announced the awarding of a US$ 4.6 million grant to Color, a biotechnology company in Burlingame, California, to facilitate advanced research on BRCA mutations associated with breast cancer.

“Increasing genetic mutations complexities is leading to the emergence of highly life-threatening and debilitating disorders, prompting healthcare providers to incorporate advanced diagnostic solutions to mitigate the impact of such diseases,” remarks a Fact.MR analyst.   

Request a report sample to gain comprehensive insights at

Key Takeaways from Fact.MR’s Genetic Analyzer Systems Study

  • By type, PCR analyzer systems to remain preferred, demand for next-generation sequencing to incline
  • Based on application, drug discovery is emerging as a primary deployment area
  • US to emerge as the market hegemon, attributed to intense R&D programs to combat various disorders, including down syndrome
  • Robust government support for funding genetics research to stimulate adoption across the UK
  • Germany experiencing an incline amid accelerating research initiatives for lynch syndrome amongst colorectal cancer patients
  • High incidence of cystic fibrosis is uplifting genetic analyzer systems adoption in France for diagnostic testing
  • India to emerge as a heavyweight in the genetic analyzer systems domain, supported by the Genome India Project

Genetic Analyzer Systems Market- Prominent Drivers

  • Integration of software support and algorithm based sequencing strain reduction to widen growth prospects
  • Growing incidences of genetic mutations amongst large population groups to enhance adoption of advanced genetic analyzer systems
  • Opportunities are aplenty across the oncology segment, with experts discovering novel breakthroughs in genetic detection approaches

Genetic Analyzer Systems Market- Key Restraints

  • Dearth of skilled professionals in handling advanced genetic analyzer systems is restraining adoption across multiple settings
  • High capital investments with respect to installing advanced equipment is deterring small-scale practitioners from adopting these systems

Discover more about the genetic analyzer systems market with figures, data tables and the table of contents. You will also find detailed market segmentation on

Competitive Landscape

Key players operating in the genetic analyzer systems market include Thermo Fisher Scientific Inc., Abbott laboratories, AutoGenomics Inc., BioRad Laboratories, Celera Group, PerkinElmer Inc., Quest Diagnostics Inc., ELITech Group, Applied Biosystems Inc., F. Hoffmann-La Roche AG, and Transgenomic Inc. among others.

Development and introduction of novel testing approaches remains a primary expansion strategy for the aforementioned manufacturers. For instance, in March 2021, Thermo Fisher Scientific announced the completion of US FDA listing for the Applied Biosystems QuantStudio 5 Dx RT-PCR System which enables clinical laboratories and assay developers fulfil testing demands and enhance molecular diagnostic workflow.

Likewise, AutoGenomics Inc. offers the INFINITI® System, a multiplexing, continuous flow, random access microarray platform that offers high performance genetic marker detection with varying options in automation and throughput. The system is designed to measure fluorescence signals of labeled DNA target hybridized to novel BioFilmChip® microarrays using Target Signal Amplification chemistry.

More Insights on the Genetic Analyzer Systems Market

In its ongoing study, Fact.MR offers unbiased analysis of the global genetic analyzer systems market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of type (PCR, DNA microarrays, next-generation sequencing, gene expression analysis and northern blotting) and application (diagnostic centers, research & development centers, academic research, drug discover and others) across seven major regions (North America, Latin America, Europe, CIS & Russia, Japan, APEJ and Middle East & Africa).

Request For No-Obligation Table Of Content

Explore Fact.MR’s Coverage on the Healthcare Domain

Prefilled Auto Injectors Market: Increasing demand for minimally invasive treatments is prompting medical device manufacturers to shift their focus towards development of more reliable, accurate and easy to use auto-injectors. This Fact.MR report analyzes the expansion of global prefilled auto-injectors market till date, and provides key insights on the growth of the market during the upcoming decade.

Urodynamic Devices Market: The scope of Fact.MR’s report is to analyze the global urodynamic devices market for the upcoming forecast period and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global urodynamic devices market can benefit from the analysis offered in this report.

Cell Lines Market: Fact.MR’s extensive coverage on the cell lines market provides an in-depth analysis of the prominent drivers anticipated to shape future growth trajectory of the landscape. The report sheds light on the key segments’ respective shares across prominent geographies. Moreover, a detailed competitive landscape further enhances reliability of this research study.    

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.    

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Follow Us: LinkedIn | Twitter
Market Intelligence Services:
Source: Fact.MR

Back to news